Penyakit Parkinson: Tinjauan Tentang Salah Satu Penyakit Neurodegeneratif yang Paling Umum
Downloads
Penyakit Parkinson (PP) adalah penyakit neurodegeneratif paling umum ke dua yang melibatkan hilangnya neuron dopaminergik di otak tengah yang menyebabkan gejala motorik dan nonmotorik pada pasien yang mengalaminya. Gejala motorik ini dapat dikelola dan dikendalikan dalam jangka waktu tertentu dengan menggunakan obat-obatan seperti levodopa. PP mempengaruhi jutaan orang di seluruh dunia, oleh karena itu tinjauan pustaka tinjauan pustaka tentang PP menjadi penting dan kami akan menyampaikan berbagai hal penting dari PP mulai dari patofisiologi hingga tindakan pengobatan baik medikamentosa maupun tindakan intervensi.
Rizek P, Kumar N, Jog MS. An update on the diagnosis and treatment of Parkinson disease. CMAJ. 2016;188(16):1157–65. doi:10.1503/cmaj.151179
DeMaagd G, Philip A. Parkinson's disease and its management part 1 : Disease entity, risk factors, pathophysiology, clinical presentation and diagnosis. P T. 2015;40(8):504–32.
Safitri I, Hidayati HB, Turchan A, Suhartati, Khaerunnisa S. Solanum betaceum improves cognitive function by decreasing N-Methyl-D-aspartate on Alzheimer rats model. Int J Appl Pharm. 2019;11(Special Issue 5):167–70. doi: 10.22159/ijap.2019.v11s5.T1015
Dahodwala N, Willis AW, Li P, Doshi JA. Prevalence and correlates of anti-parkinson drug use in a nationally representative sample. Moc Disord Clin Pract. 2016;4(3):335–41. doi: 10.1002/mdc3.12422
Haddad F, Sawalha M, Khawaja Y, Najjar A, Karaman R. Dopamine and levodopa prodrugs for the treatment of Parkinson's disease. Molecules. 2018;23(1):1-17.doi: 10.3390/molecules23010040
Levodopa - drug and medication information. US Natl Libr Med Natl Cent Biotechnol Inf. 2020;
Prakash KM, Nadkarni N V., Lye WK, Yong MH, Tan EK. The impact of non-motor symptoms on the quality of life of parkinson's disease patients: A longitudinal study. Eur J Neurol. 2016;23(5):854–60. doi:10.1111/ene.12950.
Menon B, Nayar R, Kumar S, Cherkil S, Venkatachalam A, Surendran K, et al. Parkinson's disease, depression, and quality-of-life. Indian J Psychol Med. 2015;37(2):144–8. doi:10.4103/0253-7176.155611
Kalia L V., Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896–912.
Sonne J, Reddy V, Beato MR. Neuroanatomy, substantia nigra. StatPearls. StatPearls Publishing; 2018.
Young CB, Reddy V, Sonne J. Neuroanatomy, basal ganglia. StatPearls. StatPearls Publishing; 2019.
Magrinelli F, Picelli A, Tocco P, Federico A, Roncari L, Smania N, et al. Pathophysiology of motor dysfunction in parkinson's disease as the rationale for drug treatment and rehabilitation. Parkinsons Dis. 2016;2016. doi:10.1155/2016/9832839
Helmich RC, Dirkx MF. Pathophysiology and management of parkinsonian tremor. Semin Neurol. 2017;37(2):127–34. doi:10.1055/s-0037-1601558
Kouli A, Torsney KM, Kuan W-L. Parkinson's disease: etiology, neuropathology, and pathogenesis. In: parkinson's disease: Pathogenesis and clinical aspects. Codon Publications; 2018. p. 3–26.
Marsili L, Rizzo G, Colosimo C. Diagnostic criteria for Parkinson's Disease: From James Parkinson to the concept of prodromal disease. Front Neurol. 2018;9(156):1–10. doi: 10.3389/fneur.2018.00156
Armstrong MJ, Okun MS. Diagnosis and treatment of parkinson disease: A review. JAMA - J Am Med Assoc. 2020;323(6):548–60. doi:10.1001/jama.2019.22360
Clarke CE. Parkinson's disease. Br Med J. 2007;335(7617):441–5. doi:10.1136/bmj.39289.437454.AD
Greenland JC, Barker RA. The Differential Diagnosis of parkinson ' s disease. In: Parkinson's disease. Exon; 2018. p. 109–28.
Ellis JM, Fell MJ. Current approaches to the treatment of parkinson's disease. Bioorganic Med Chem Lett. 2017;27(18):4247–55. doi:10.1016/j.bmcl.2017.07.075
Keener AM, Bordelon YM. Parkinsonism. Semin Neurol. 2016;36(4):330–4. doi:10.1055/s-0036-1585097
Shrimanker I, Tadi P, Sánchez-Manso JC. Parkinsonism. In: Encyclopedia of the Neurological Sciences. Elsevier Inc.; 2014. p. 820–3.
Iarkov A, Barreto GE, Grizzell JA, Echeverria V. Strategies for the treatment of parkinson's disease: Beyond dopamine. Front Aging Neurosci. 2020;12(4):1–20. doi:10.3389/fnagi.2020.00004
Titova N, Martinez-Martin P, Katunina E, Chaudhuri KR. Advanced parkinson's or "complex phase” parkinson's disease? Re-evaluation is needed. J Neural Transm. 2017;124(12):1529–37. doi:10.1007/s00702-017-1799-3
Luquin MR, Kulisevsky J, Martinez-Martin P, Mir P, Tolosa ES. Consensus on the definition of advanced parkinson's disease: A Neurologists-Based delphi study (CEPA Study). Parkinsons Dis. 2017;2017:1-8. doi:10.1155/2017/4047392
Krüger R, Klucken J, Weiss D, Tönges L, Kolber P, Unterecker S, et al. Classification of advanced stages of Parkinson's disease: translation into stratified treatments. J Neural Transm. 2017;124(8):1015–27.
Fang JY, Tolleson C. The role of deep brain stimulation in parkinson's disease: An overview and update on new developments. Neuropsychiatr Dis Treat. 2017;13:723–32.
Copyright (c) 2021 Safia Alia, Hanik Badriyah Hidayati, Muhammad Hamdan, Priya Nugraha, Achmad Fahmi, Agus Turchan, Yudha Haryono
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
